Amneal Pharmaceuticals, Inc. (AMRX) shares surged 9.95% in pre-market trading on Thursday, following the release of its second-quarter 2026 financial results that exceeded analyst expectations.

The company reported adjusted earnings per share of $0.30, significantly beating the consensus estimate of $0.22. Revenue for the quarter rose 10% year-over-year to $796 million, also topping the analyst forecast of $768.2 million. GAAP net income more than doubled to $58 million, driven by strong performance in the specialty and affordable medicines segments. Additionally, Amneal raised its full-year 2026 guidance, now projecting revenue between $3.10 billion and $3.20 billion and adjusted EBITDA of $750 million to $780 million, both above prior ranges.

The pre-market rally reflects investor optimism around the company’s robust earnings beat and improved outlook, fueled by branded product growth and new product launches across its portfolio.